MMS dose-dependent hypermutation phenotype in the rad9Δ mutant. A) Log-phase wild type (BY4741) and rad9Δ (CB1021) cells (BY4741 background) were grown in the presence of 0.01% MMS for 5 hours and then harvested for determination of survival (62±5% and 4.8±0.5% for wild type and rad9Δ cells, respectively) and induction of mutation to CanR (upper panel). In parallel, the survival and mutation rates were also determined for wild type and rad9Δ cells grown for a shorter time (0.5 hour) in higher-concentration (0.05%) of MMS (lower panel, the survival rate for wild type and rad9Δ were 98±3% and 73±4%, respectively). Each strain was tested in triplicate, and the error bars represent the standard deviations. B) Yeast cells from a different genetic background (A364a) were tested for mutation to CanR as well as induction of SCE after MMS exposure (as above). The survival rate for wild type (yMP10381) and rad9Δ (yMP11030) were 79±6% and 3.1±0.2%, respectively in the 0.01%/5 hour MMS treatment; the survival rate for wild type and rad9Δ were 88±6% and 84±2%, respectively in the 0.05%/0.5 hour MMS treatment. Each strain was tested in triplicate, and the error bars represent standard deviations. C) The MMS-induced hypermutability of rad9Δ is REV3-dependent. Wild type (yMP10381), rad9Δ (yMP11030), rev3Δ (yMP10382), and rad9Δ rev3Δ (yDH51, yDH52, yDH53) cells were tested for survival and mutation to CanR after treatment with a very low concentration of MMS (0.001%) for 5 hours (low concentration MMS was required due to the high sensitivity of the rad9Δ rev3Δ double mutant, Table 2). The survival rate for wild type, rad9Δ, rev3Δ and rad9Δ rev3Δ cells were 93±3%, 63±4%, 90±12% and 12±1%, respectively. Each strain was tested in triplicate, and the error bars represent standard deviations.